UBS Makes Year-End Changes to Red-Hot Quality Growth at a Reasonable Price Portfolio

Investing

Published: December 15, 2015 9:50 am

Last Updated: January 13, 2020 4:05 pm

In what has been a very difficult year for investors, one portfolio that we cover on a regular basis has done outstanding. In a new report, the analysts at UBS make a late 2015 addition to the firm’s Quality Growth at a Reasonable Price (Q-GARP) portfolio, which has had another market beating year for investors.

The Q-GARP portfolio through last week was up a solid 5.3% this year, versus the -0.3% for the S&P 500. Since the inception of the portfolio in 2007, the Q-GARP stocks are up a sparkling 123.1%, versus the S&P 500’s 58.1%, a relative outperformance of a stunning 58.1%.

The company adds a top medical technology company to the portfolio, and we screened for the top dividend-paying stocks that also make the cut.

Becton, Dickinson

This top health care company makes its debut on the Q-GARP list. Becton, Dickinson and Co. (NYSE: BDX) is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs.

The company’s innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes.